belantamab mafodotin + pomalidomide + dexamethasone

Belantamab mafodotin (GSK2857916) is a humanized IgG1 antibody-drug conjugate that targets B-cell maturation antigen (BCMA), a protein expressed on malignant plasma cells. The antibody is conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) via a non-cleavable linker, enabling targeted delivery of the cytotoxin to BCMA-expressing cells. Upon binding, the drug is internalized and releases MMAF inside the cell, causing cell-cycle arrest and apoptosis. Belantamab mafodotin also enhances immune-mediated killing through antibody-dependent cellular cytotoxicity and phagocytosis due to its afucosylation[2][4][5][8]. Pomalidomide is an immunomodulatory small molecule used in multiple myeloma therapy; it exerts anti-neoplastic effects by modulating cytokine production, inhibiting angiogenesis, and enhancing T-cell and natural killer cell activity[6][7]. Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties commonly used as part of combination regimens for multiple myeloma. This three-drug combination has been investigated for relapsed/refractory multiple myeloma.

Brand names

Blenrep

Other names

belantamab mafodotinpomalidomidedexamethasone